All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF WASHINGTON

UNIVERSITY OF WASHINGTON

Projects attributed to UNIVERSITY OF WASHINGTON within this analysis sample.

In This Analysis
Projects
1
NIH Funding
$379K
Projects(1)
ProjectPICategoryFunding
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
5R01CA258997-05
BOWEN, STEPHEN R.Therapeutics$379K
See UNIVERSITY OF WASHINGTON’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.